HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: As a selective histone deacetylase (HDAC) inhibitor developed in China, chidamide has been applied for the treatment of refractory peripheral T-cell lymphoma (PTCL) and multiple solid tumors, including lung cancer.